Long lasting synthetic glucagon like peptide (GLP-1)
AssigneeConjuChem, Inc.
InventorsDominique Bridon, Benoit L' Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
Life of this patent
Estimating the term…
Abstract
Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
Claims21
1-19. (canceled)
A method for treating an insulinotropic peptide related disease in a patient, comprising administering to the patient an effective amount of a modified insulinotropic peptide comprising SEQ ID NO:
- 18 wherein said insulinotropic peptide related disease is obesity.
Dependencies are inferred from the claim text.